MX2022011123A - Compuestos inhibidores de phd, composiciones, y uso. - Google Patents

Compuestos inhibidores de phd, composiciones, y uso.

Info

Publication number
MX2022011123A
MX2022011123A MX2022011123A MX2022011123A MX2022011123A MX 2022011123 A MX2022011123 A MX 2022011123A MX 2022011123 A MX2022011123 A MX 2022011123A MX 2022011123 A MX2022011123 A MX 2022011123A MX 2022011123 A MX2022011123 A MX 2022011123A
Authority
MX
Mexico
Prior art keywords
pulmonary
disease
phd
kidney
acute
Prior art date
Application number
MX2022011123A
Other languages
English (en)
Spanish (es)
Inventor
Paul E Fleming
Thomas P Blaisdell
Senkara Rao Allu
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of MX2022011123A publication Critical patent/MX2022011123A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2022011123A 2020-03-20 2021-03-19 Compuestos inhibidores de phd, composiciones, y uso. MX2022011123A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062992585P 2020-03-20 2020-03-20
PCT/US2021/023219 WO2021188936A1 (en) 2020-03-20 2021-03-19 Phd inhibitor compounds, compositions, and use

Publications (1)

Publication Number Publication Date
MX2022011123A true MX2022011123A (es) 2023-01-04

Family

ID=75639962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011123A MX2022011123A (es) 2020-03-20 2021-03-19 Compuestos inhibidores de phd, composiciones, y uso.

Country Status (13)

Country Link
US (1) US20230227426A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121425A1 (cg-RX-API-DMAC10.html)
JP (2) JP7768890B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220156889A (cg-RX-API-DMAC10.html)
CN (2) CN115551845B (cg-RX-API-DMAC10.html)
AR (1) AR121618A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021239378A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018877A2 (cg-RX-API-DMAC10.html)
CA (1) CA3176140A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022014490A2 (cg-RX-API-DMAC10.html)
IL (1) IL296631A (cg-RX-API-DMAC10.html)
MX (1) MX2022011123A (cg-RX-API-DMAC10.html)
WO (1) WO2021188936A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
AR121626A1 (es) 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
AP2015008783A0 (en) * 2013-03-29 2015-10-31 Takeda Pharmaceutical 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors

Also Published As

Publication number Publication date
CN115551845B (zh) 2025-02-28
CA3176140A1 (en) 2021-09-23
CN115551845A (zh) 2022-12-30
AR121618A1 (es) 2022-06-22
EP4121425A1 (en) 2023-01-25
KR20220156889A (ko) 2022-11-28
CO2022014490A2 (es) 2022-10-21
JP2026021443A (ja) 2026-02-10
JP7768890B2 (ja) 2025-11-12
US20230227426A1 (en) 2023-07-20
JP2023518953A (ja) 2023-05-09
WO2021188936A1 (en) 2021-09-23
CN119823097A (zh) 2025-04-15
BR112022018877A2 (pt) 2022-11-29
AU2021239378A1 (en) 2022-11-17
IL296631A (en) 2022-11-01
TW202140443A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
CO2022014587A2 (es) Compuestos inhibidores de phd, composiciones y uso
CO2022014490A2 (es) Compuestos inhibidores de phd, composiciones y uso
CU23967B1 (es) Derivados de pirazin-2-carboxamida para tratar enfermedades mediadas por el bloqueo del canal de sodio epitelial
AR121626A1 (es) Compuestos inhibidores de phd, composiciones y métodos de uso
CY1122860T1 (el) 3,5-διαμινο-6-χλωρο-ν-(ν-(4-(4-(2-(εξυλ(2,3,4,5,6-πενταϋδροξυεξυλ)αμινο)αιθοξυ)φαινυλ)βουτυλ)καρβαμιμιδοϋλ)πυραζινο-2-καρβοξαμιδιο
PE20210046A1 (es) Agonistas de fenilpirrolidinona del receptor 2 de formil peptido
AR111178A1 (es) Inhibidor de la quinasa reguladora de la señal de apoptosis
JP2009544602A5 (cg-RX-API-DMAC10.html)
AR134363A1 (es) Derivado de ácido 2-(pirrolidina-3-il)acético sustituido, método de preparación y uso de este
JP2008546770A5 (cg-RX-API-DMAC10.html)
MX2025005440A (es) Agonistas del receptor del peptido-1 similar al glucagon
AR127507A1 (es) Agonistas de rxfp1
MX2024011179A (es) Compuestos multiciclicos
CO2025005721A2 (es) Derivados de benzimidazol cíclico como inhibidores de cgas
CL2025001166A1 (es) Derivados de piridina cíclico como inhibidores de cgas
AR057849A1 (es) Dialurrea para el tratamiento de hipertension pulmonar
BR112021024955A2 (pt) Inibidores de piridila ou pirimidila da quinase mtor
AR123243A1 (es) Compuestos inhibidores del phd, composiciones y métodos de uso
BR112023000344A2 (pt) Agonistas de receptor de peptídeo de formila de pirazolona 2
AR132818A1 (es) Compuestos para la degradación de la cinasa egfr
NO20081736L (no) Antitumormidler
AR127559A1 (es) Compuestos, composiciones y métodos
CN115066417A (zh) 凝血因子XIa抑制剂
MX2022004809A (es) Composiciones para prevenir o tratar enfermedad pulmonar obstructiva cronica (epoc).
AR131016A1 (es) DERIVADOS DE BENZIMIDAZOL CÍCLICO COMO INHIBIDORES DE cGAS